IP Library Granted Patent US 7,053,094
Granted Patent B2
US 7,053,094 · App. 11/040,478 · Granted May 30, 2006

Compositions and methods for treating heart failure

Assignee: Cytokinetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,094
App. No.
11/040,478
Granted
May 30, 2006
Kind
B2
Abstract

Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Claims (37)

1. A method of increasing contractile force in cardiac muscle fiber, comprising contacting cardiac muscle fiber with a compound represented by Formula I

wherein:

R 1 is alkyl, substituted alkyl, aryl, substituted aryl, hetoroaryl or substituted heteroaryl;

R 2 is acetyl, acetylamino, acetylene, alkoxycarbonyl, carboxamido, cyano, halo, heteroaryl, hydrogen, nitrile, nitro or trifluoromethyl; and

R 3 is aryl, substituted aryl, heteroaryl or substituted heteroaryl; or a single stereoisomer, or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 where R 1 is phenyl, substituted phenyl or pyridinyl.

3. The method of claim 2 where R 1 is 3-chlorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 3-methylphenyl, pyzidin-2-yl or pyridin-3-yl.

4. The method of claim 1 where R 2 is acetyl, acetylene, alkoxycarbonyl, cyano, halo, heteroaryl, hydrogen, nitro or trifluoromethyl.

5. The method of claim 3 where R 2 is acetylene, cyano, exthoxycarbonyl, fluoro, hydrogen, nitro, oxazol-2-yl, pyridin-2-yl, pyrimidin-2-yl, thiazol-2-yl or trifluoromethyl.

6. The method of claim 1 where R 3 is:

phenyl, optionally substituted with lower alkoxy, lower alkyl, halo, hydroxy, hydroxy-lower alkyl or nitro; or

benzodioxolyl, furanyl, indolyl, isoxazolyl, pyrazolyl, pyridinyl or thiophenyl, optionally substituted with lower alkyl, lower alkoxy, or halo.

7. The method of claim 6 where R 3 is 3-hydroxyphenyl, 4-hydroxyphenyl, 4-fluorophenyl, isoxazol-5-yl, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl or 5-methyl-thiophen-2-yl.

8. The method of claim 1 where R 1 is substituted phenyl and R 2 nitro.

9. The method of claim 8 where where R 1 is 4-fluorophenyl.

10. The method of claim 1 where R 1 is heteroaryl and R 2 is fluoro.

11. The method of claim 10 where where R 1 is pyridin-3-yl.

12. The method of claim 1 where R 1 is heteroaryl and R 2 is nitro.

13. The method of claim 12 where where R 1 is pyridin-3-yl.

14. The method of claim 13 where R 3 is phenyl, 4-fluorophenyl, 4-cyanophenyl, 4-methoxyphenyl or 4-methylphenyl.

15. The method of claim 1 where the compound is:

4-fluoro-N-[nitro-5-(pyidin-3-yloxy)-phenyl]-benzamide;

N-[3-(4-fluoro-phenoxy)-(5-nitro-phenyl]-isonicotinamide;

4-fluoro-N-[3-(pyridin-3-yloxy)-phenyl]-benzamide;

thiophene-2-carboxylic acid [3-(4-fluoro-phenoxy)-5-nitro-phenyl-amide;

isoxazole-5-carboxylic acid [3-(4-fluoro-phenoxy)-5-nitro-phenyl-amide;

N-[3-cyano-5-(pyridin-3-yloxy)-phenyl]]-4-fluoro-benzamide;

4-fluoro-N-[3-(pryidin-3-yloxy)-5-trifluoromethyl-phenyl]-benzamide;

3-(4-fluoro-benzoylamino)-5-(pyridin-3-yloxy)-benzoic acid ethyl ester;

5-methyl-thiophene-2-carboxylic acid [3-nitro-5-(pyridin-3-yloxy)phenyl]-amide;

4-fluoro-N-[3-pyridin-2-yl-5-(pyridin-3-yloxy)-phenyl]-benzamide;

4-fluoro-N-[3-pyrazin-2-yl-5-(pyridin-3-yloxy)-phenyl]-benzamide;

4-fluoro-N-[3-nitro-5-(pyridin-2-yloxy)-phenyl]-benzamide;

N-[3-fluoro-5-(pyridin-3-yloxy)-phenyl]-3-hydroxy-benzamide;

N-[3-fluoro-5-(pyridin-3-yloxy)-phenyl]-4-hydroxy-benzamide;

N-[3-fluoro-5-(pyridin-3-yloxy)-phenyl]-nicotinamide; or

isoxazole-5-carboxylic acid [3-fluoro-5-(pyridin-3-yloxy)-phenyl)-amide.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jan 26, 2017
From: AMGEN INC.
To: CYTOKINETICS, INCORPORATED
Reel/Frame 041094/0653 →
SECURITY AGREEMENT Recorded Jan 3, 2007
From: CYTOKINETICS, INCORPORATED
To: AMGEN, INC.
Reel/Frame 018700/0104 →
Continuity (3)
Continuation 1032721900 · Dec 20, 2002
Provisional Application 6034308800 · Dec 21, 2001
Related Publication 20050148638A1 · Jul 7, 2005